Intracranial Hemorrhage clinical trials at UCLA

3 in progress, 2 open to eligible people

Showing trials for

  • Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

    open to eligible people ages 18 years and up

    Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

    Los Angeles, California and other locations

  • Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

    open to eligible people ages 18-80

    The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

    Los Angeles, California and other locations

  • MIND: Artemis in the Removal of Intracerebral Hemorrhage

    Sorry, in progress, not accepting new patients

    The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).

    Los Angeles, California and other locations

Our lead scientists for Intracranial Hemorrhage research studies include .

Last updated: